Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Analogues of angiotensin II|
|Abstract:||Novel hepta- and octapeptides of the formula: ##SPC1## Wherein R is hydrogen, succinyl, L-aspartyl, L-sarcosyl, L-seryl, succinamyl, or D- or L-asparaginyl and R.sub.1 is an L-alanine, L- or D-leucine, glycine or L-isoleucine residue upon intravenous infusion to animals inhibit blood pressure response to angiotensin amide.|
|Inventor(s):||Sipos; Frank (Norwich, NY), Pals; Donald T. (Oxford, NY), Denning; George S. (Norwich, NY)|
|Assignee:||Morton-Norwich Products, Inc. (Norwich, NY)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.